From NASDAQ.: 2024-06-15 01:54:00

Moderna announced positive results from the pivotal phase III NextCOVE study for its refrigerator-stable COVID-19 vaccine, mRNA-1283, in individuals aged 12 and older. The study showed non-inferior efficacy of mRNA-1283 compared to the previous bivalent Omicron-targeting vaccine, mRNA-1273.222, with higher efficacy results. The vaccine offers longer shelf life and storage advantages.

Results from the study emphasize Moderna’s combination vaccines. Positive data was also reported on mRNA-1083, a combination of mRNA-1283 and an influenza vaccine, showing higher immune responses against both influenza and COVID-19 than separate vaccines. This could help improve vaccine uptake and convenience. Moderna plans to submit regulatory filings and aims for market availability by 2025.

Moderna’s lead in COVID-19/flu combination vaccines is highlighted, with Novavax and BioNTech/Pfizer also developing similar products. Moderna’s mRNA-1083 results show promise, positioning it ahead of competitors in late-stage study progress. Pfizer and BioNTech are evaluating their own combination vaccine after positive phase I/II results. Novavax plans to start late-stage trials this year.

The push to rebuild U.S. infrastructure will create investment opportunities. Zacks releases a Special Report on companies set to benefit from infrastructure spending. Discover 5 promising stocks in the construction, repair, and energy sectors. Download the report for free to maximize growth potential in this lucrative market.



Read more at NASDAQ.: Moderna’s (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal